Open Access

EOFAZ inhibits endothelial‑to‑mesenchymal transition through downregulation of KLF4

  • Authors:
    • Yanyan Zhang
    • Chen Li
    • Yongpan Huang
    • Shuang Zhao
    • Yini Xu
    • Yan Chen
    • Feng Jiang
    • Ling Tao
    • Xiangchun Shen
  • View Affiliations

  • Published online on: April 9, 2020     https://doi.org/10.3892/ijmm.2020.4572
  • Pages: 300-310
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Essential oil from Alpinia zerumbet rhizome (EOFAZ), which is termed Yan shanjiang in China, is extensively used as an herbal medicine in the Guizhou area and has been shown to protect against the damaging effects of cardiovascular injury in vitro and in vivo. In the present study, it was hypothesized that the protective effects of EOFAZ on transforming growth factor (TGF)‑β1‑induced endothelial‑to‑mesenchymal transition (EndMT) in human umbilical vein endothelial cells (HUVECs) were mediated by inhibition of Krüppel‑like factor 4 (KLF4). Cell motility was assessed using wound healing and Transwell assays. The expression of endothelial markers and mesenchymal markers were determined by reverse transcription‑quantitative PCR, immunofluorescence staining and western blotting, and additionally, phosphorylated NF‑κB p65 expression was determined by western blotting. Furthermore, the involvement of KLF4 in EndMT was determined using RNA interference to knockdown the expression of KLF4. TGF‑β1 treatment significantly promoted EndMT, as evidenced by downregulation of vascular endothelial‑cadherin and upregulation of α‑smooth muscle actin in HUVECs, and by enhancing cell migration. Small interfering RNA‑mediated knockdown of KLF4 reversed TGF‑β1‑induced EndMT. Additionally, treatment with EOFAZ inhibited TGF‑β1‑induced EndMT in a dose‑dependent manner. These results suggest that TGF‑β1 may induce EndMT through upregulation of KLF4, and this may be reversed by EOFAZ. Therefore, EOFAZ was shown to inhibit TGF‑β1‑induced EndMT through regulation of KLF4.
View Figures
View References

Related Articles

Journal Cover

July 2020
Volume 46 Issue 1

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Zhang, Y., Li, C., Huang, Y., Zhao, S., Xu, Y., Chen, Y. ... Shen, X. (2020). EOFAZ inhibits endothelial‑to‑mesenchymal transition through downregulation of KLF4. International Journal of Molecular Medicine, 46, 300-310. https://doi.org/10.3892/ijmm.2020.4572
MLA
Zhang, Y., Li, C., Huang, Y., Zhao, S., Xu, Y., Chen, Y., Jiang, F., Tao, L., Shen, X."EOFAZ inhibits endothelial‑to‑mesenchymal transition through downregulation of KLF4". International Journal of Molecular Medicine 46.1 (2020): 300-310.
Chicago
Zhang, Y., Li, C., Huang, Y., Zhao, S., Xu, Y., Chen, Y., Jiang, F., Tao, L., Shen, X."EOFAZ inhibits endothelial‑to‑mesenchymal transition through downregulation of KLF4". International Journal of Molecular Medicine 46, no. 1 (2020): 300-310. https://doi.org/10.3892/ijmm.2020.4572